H
Hong Luo
Researcher at Chongqing University
Publications - 20
Citations - 245
Hong Luo is an academic researcher from Chongqing University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 8 publications receiving 71 citations.
Papers
More filters
Journal ArticleDOI
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Xinan Sheng,Xieqiao Yan,Lin Wang,Yanxia Shi,Xin Yao,Hong Luo,Benkang Shi,Ji-Yan Liu,Zhisong He,Guohua Yu,Jianming Ying,Weiqing Han,Changlu Hu,Yun Ling,Zhihong Chi,Chuanliang Cui,Lu Si,Jianmin Fang,Aiping Zhou,Jun Guo +19 more
TL;DR: RC48-ADC demonstrated a promising efficacy with a manageable safety profile in patients with HER2+ locally advanced or mUC who had failed at least one line of systemic chemotherapy.
Journal ArticleDOI
Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
Ai Ping Zhou,Yuxian Bai,Yan Song,Hong Luo,Xiu Bao Ren,Xiuwen Wang,Benkang Shi,Cheng Fu,Ying Cheng,Ji-Yan Liu,Shukui Qin,Jun Li,Hanzhong Li,Xianzhong Bai,Dingwei Ye,Jinwan Wang,Jianhui Ma +16 more
TL;DR: The clinical efficacy of anlotinib was similar to that of sunitinib as the first-line treatment for mRCC, but with a more favorable safety profile.
Journal ArticleDOI
Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.
Jianhui Ma,Yan Song,Jianzhong Shou,Yuxian Bai,Hanzhong Li,Xiaodong Xie,Hong Luo,Xiubao Ren,Ji-Yan Liu,Dingwei Ye,Xianzhong Bai,Cheng Fu,Shukui Qin,Jinwan Wang,Aiping Zhou +14 more
TL;DR: Anlotinib showed promising efficacy as well as favorable safety as second-line treatment for patients with mRCC as assessed in a single-arm, open-label, phase 2 study.
Journal ArticleDOI
Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study.
Yuan-Yuan Qu,Hailiang Zhang,Hongqian Guo,Hong Luo,Qing Zou,Nianzeng Xing,Shujie Xia,Zhongquan Sun,Xuepei Zhang,Chaohong He,Jinling Cai,Xiao Zhang,Quanren Wang,Dingwei Ye +13 more
TL;DR: Camrelizumab plus famitinib showed potent and enduring antitumor activity in patients with advanced or metastatic RCC, both in treatment-naive and previously treated population as mentioned in this paper.
Journal ArticleDOI
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.
Weijie Gu,Weiqing Han,Hong Luo,Fangjian Zhou,Dalin He,Lulin Ma,Hongqian Guo,Chaozhao Liang,Tie Chong,Jun Jiang,Zhixin Chen,Yong Wang,Qing Zou,Ye Tian,J. Xiao,Jian Huang,Shaoxin Zhu,Qiang Yong,Xiaoping Zhang,Hanzhong Li,Xinfeng Yang,Chunxia Chen,Junliang Li,Chunlei Jin,Xiaojing Zhang,Dingwei Ye +25 more
TL;DR: In this paper , the authors evaluated the efficacy and safety of rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy (ADT) for high-volume, metastatic, hormone-sensitive prostate cancer.